Fulcrum Therapeutics(FULC)

Search documents
Fulcrum Therapeutics(FULC) - 2019 Q4 - Earnings Call Transcript
2020-03-05 19:21
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2019 Earnings Conference Call March 5, 2020 8:00 AM ET Company Participants Christi Waarich - Director of Investor Relations and Corporate Communications Robert Gould - President and Chief Executive Officer Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Diego Cadavid - Senior Vice President of Clinical Development Conference Call Participants Matthew Harrison - Morgan Stanley Joseph Schwartz - SVB Leerink Tazeen Ahmad - Bank of Amer ...
Fulcrum Therapeutics(FULC) - 2019 Q3 - Earnings Call Transcript
2019-11-14 17:37
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2019 Earnings Conference Call November 14, 2019 8:00 AM ET Company Participants Peter Thomson – Vice President-Finance and Accounting Robert Gould – President and Chief Executive Officer Bryan Stuart – Chief Operating Officer Conference Call Participants Dae Gon Ha – SVB Leerink Matthew Harrison – Morgan Stanley Operator Good morning and welcome to the Fulcrum Therapeutics Third Quarter 2019 Conference Call. Currently, all participants are in a listen-only mode. T ...
Fulcrum Therapeutics(FULC) - 2019 Q3 - Quarterly Report
2019-11-14 13:50
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other j ...
Fulcrum Therapeutics(FULC) - 2019 Q2 - Quarterly Report
2019-08-26 11:43
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-38978 WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other jurisd ...